details

Peer companies

;

Share Market News

Net sales declined -20.85%  to  Rs. 1093.10 million from Rs. 1381.00 millions.Net profit was down at Rs. 7.90  millions against Rs. 100.00 millions recorded in the corresponding quarter a year ago.The net profit spiraled down by -92.10%.The Operating Profit of the company witnessed a decrease to 56.90 millions from 187.80 millions. (Rs. in Million) Quarter ended Year to Date Year ended 201906 201806 % Var 201906 201806 % Var 201903 201803 % Var Sales 1093.10 1381.00 -20.85 1093.10 1381.00 -20.85 4906.80 5638.90 -12.98 Other Income 108.90 222.80 -51.12 108.90 222.80 -51.12 782.60 1718.30 -54.45 PBIDT 56.90 187.80 -69.70 56.90 187.80 -69.70 905.40 1655.80 -45.32 Interest 11.60 15.30 -24.18 11.60 15.30 -24.18 15.90 55.30 -71.25 PBDT 45.30 172.50 -73.74 45.30 172.50 -73.74 889.50 1600.50 -44.42 Depreciation 32.20 6.60 387.88 32.20 6.60 387.88 31.80 25.30 25.69 PBT 13.10 165.90 -92.10 13.10 165.90 -92.10 857.70 1575.20 -45.55 TAX 5.20 65.90 -92.11 5.20 65.90 -92.11 340.00 791.60 -57.05 Deferred Tax -0.50 0.60 -183.33 -0.50 0.60 -183.33 7.30 -4.70 -255.32 PAT 7.90 100.00 -92.10 7.90 100.00 -92.10 517.70 783.60 -33.93 Equity 123.40 123.40 0.00 123.40 123.40 0.00 123.40 123.40 0.00 PBIDTM(%) 5.21 13.60 -61.72 5.21 13.60 -61.72 18.45 29.36 -37.16

The sales declined to Rs. 1356.20 millions for the December 2018 quarter as compared to Rs. 1561.00 millions during the corresponding quarter last year.Profit after Tax for the quarter ended December 2018 saw a decline of -31.32% from Rs. 187.40 millions to Rs. 128.70  millions.Operating Profit reported a sharp decline to 249.70 millions from 262.70 millions in the corresponding previous quarter. (Rs. in Million) Quarter ended Year to Date Year ended 201812 201712 % Var 201812 201712 % Var 201803 201703 % Var Sales 1356.20 1561.00 -13.12 3803.00 4385.70 -13.29 5638.90 6562.30 -14.07 Other Income 114.70 144.50 -20.62 648.30 622.30 4.18 1718.30 710.00 142.01 PBIDT 249.70 262.70 -4.95 572.50 778.80 -26.49 1655.80 960.40 72.41 Interest 0.30 3.20 -90.63 15.90 3.90 307.69 55.30 7.20 668.06 PBDT 249.40 259.50 -3.89 556.60 774.90 -28.17 1600.50 953.20 67.91 Depreciation 9.50 5.40 75.93 22.70 18.90 20.11 25.30 35.90 -29.53 PBT 239.90 254.10 -5.59 533.90 756.00 -29.38 1575.20 917.30 71.72 TAX 111.20 66.70 66.72 211.50 237.10 -10.80 791.60 345.10 129.38 Deferred Tax 4.00 -19.90 -120.10 -9.30 -16.30 -42.94 -4.70 -19.00 -75.26 PAT 128.70 187.40 -31.32 322.40 518.90 -37.87 783.60 572.20 36.95 Equity 123.40 140.70 -12.30 123.40 140.70 -12.30 123.40 140.70 -12.30 PBIDTM(%) 18.41 16.83 9.40 15.05 17.76 -15.23 29.36 14.64 100.64

The revenue zoomed 20.28% to Rs. 1381.00 millions for the quarter ended June 2018 as compared to Rs. 1148.20 millions during the corresponding quarter last year.A good growth in profit of 42.25% reported to Rs. 100.00  millions over Rs. 70.30 millions of corresponding previous quarter.Operating profit surged to 187.80 millions from the corresponding previous quarter of 105.80 millions. (Rs. in Million) Quarter ended Year to Date Year ended 201806 201706 % Var 201806 201706 % Var 201803 201703 % Var Sales 1381.00 1148.20 20.28 1381.00 1148.20 20.28 5638.90 6562.30 -14.07 Other Income 222.80 226.80 -1.76 222.80 226.80 -1.76 1718.30 710.00 142.01 PBIDT 187.80 105.80 77.50 187.80 105.80 77.50 1655.80 960.40 72.41 Interest 15.30 0.20 7550.00 15.30 0.20 7550.00 55.30 7.20 668.06 PBDT 172.50 105.60 63.35 172.50 105.60 63.35 1600.50 953.20 67.91 Depreciation 6.60 7.10 -7.04 6.60 7.10 -7.04 25.30 35.90 -29.53 PBT 165.90 98.50 68.43 165.90 98.50 68.43 1575.20 917.30 71.72 TAX 65.90 28.20 133.69 65.90 28.20 133.69 791.60 345.10 129.38 Deferred Tax 0.60 0.20 200.00 0.60 0.20 200.00 -4.70 -19.00 -75.26 PAT 100.00 70.30 42.25 100.00 70.30 42.25 783.60 572.20 36.95 Equity 123.40 140.70 -12.30 123.40 140.70 -12.30 123.40 140.70 -12.30 PBIDTM(%) 13.60 9.21 47.58 13.60 9.21 47.58 29.36 14.64 100.64

Net sales declined -5.04%  to  Rs. 1561.00 million from Rs. 1643.80 millions.Net Profit recorded in the quarter ended December 2017 rise to 43.82% to Rs. 187.40  millions  compared to R. 130.30 millions in corresponding previous quarter.Operating profit surged to 262.70 millions from the corresponding previous quarter of 220.40 millions. (Rs. in Million) Quarter ended Year to Date Year ended 201712 201612 % Var 201712 201612 % Var 201703 201603 % Var Sales 1561.00 1643.80 -5.04 4385.70 5107.50 -14.13 6562.30 6899.00 -4.88 Other Income 144.50 150.80 -4.18 622.30 554.50 12.23 701.50 808.80 -13.27 PBIDT 262.70 220.40 19.19 778.80 871.50 -10.64 960.40 1150.70 -16.54 Interest 3.20 2.50 28.00 3.90 3.30 18.18 7.20 2.10 242.86 PBDT 259.50 217.90 19.09 774.90 868.20 -10.75 953.20 1148.60 -17.01 Depreciation 5.40 8.00 -32.50 18.90 22.50 -16.00 35.90 34.90 2.87 PBT 254.10 209.90 21.06 756.00 845.70 -10.61 917.30 1113.70 -17.63 TAX 66.70 79.60 -16.21 237.10 302.60 -21.65 345.10 388.80 -11.24 Deferred Tax -19.90 -12.00 65.83 -16.30 -15.00 8.67 -19.00 -22.20 -14.41 PAT 187.40 130.30 43.82 518.90 543.10 -4.46 572.20 724.90 -21.06 Equity 140.70 140.70 0.00 140.70 159.80 -11.95 140.70 159.80 -11.95 PBIDTM(%) 16.83 13.41 25.51 17.76 17.06 4.07 14.64 16.68 -12.26

Novartis India is currently trading at Rs. 679.05, up by 30.25 points or 4.66% from its previous closing of Rs. 648.80 on the BSE.The scrip opened at Rs. 690.00 and has touched a high and low of Rs. 697.30 and Rs. 675.10 respectively. So far 137242 shares were traded on the counter.The BSE group `B` stock of face value Rs. 5 has touched a 52 week high of Rs. 758.00 on 18-Apr-2017 and a 52 week low of Rs. 579.00 on 11-Aug-2017.Last one week high and low of the scrip stood at Rs. 697.30 and Rs. 617.20 respectively. The current market cap of the company is Rs. 1907.24 crore.The promoters holding in the company stood at 73.40%, while institutions and non-institutions held 1.33% and 25.27% respectively.Novartis India is planning for buyback of its equity shares. The meeting of the Board of Directors of the Company will be held on September 25, 2017, to consider the same proposal, constitution of buyback committee, and appointment of intermediaries in accordance with all applicable provisions of law.Novartis is a world leader in the research and development of products to protect and improve health and well-being. The company has core businesses in pharmaceuticals, vaccines, consumer health, generics, eye care and animal health.

Novartis India has submitted the Shareholding Pattern for the Period Ended December 31, 2016. The above information is a part of company’s filings submitted to BSE.

Novartis India has informed that the meeting of the Board of Directors of the Company will be held on July 28, 2016, to consider unaudited financial results of the Company for first quarter ended June 30, 2016.The above information is a part of company’s filings submitted to BSE.

Novartis India has informed that the Annual General Meeting (AGM) of the Company will be held on July 29, 2016.The above information is a part of company’s filings submitted to BSE.

Novartis India has informed that the Board of Directors of the Company at its meeting held on June 13, 2016, has approved appointment of Monaz Noble as Additional Director on the Board of Directors of the Company with effect from June 13, 2016 to hold the office of Additional Director up to the date of Annual General Meeting (‘AGM’). Subject to the approval of Members at the forthcoming AGM, the Board also approved appointment of Monaz Noble as Whole Time Director for a period of five years with effect from June 13, 2016. Noble is not related to any Director of the Company.The above information is a part of company’s filings submitted to BSE.

Novartis India has submitted a Copy of the Notice of Postal Ballot.The above information is a part of company’s filings submitted to BSE.

Novartis India has informed about Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.The above information is a part of company’s filings submitted to BSE.

Novartis India has informed about slump Sale of Novartis India Limited's Animal Health Division - Transaction Update.The above information is a part of company’s filings submitted to BSE.